Observation of the Efficacy and Tolerance of Motens® (Lacidipine) in Patients With Essential Hypertension

Boehringer Ingelheim

Status: Completed

Conditions: Hypertension

Treatments: Drug: Motens® (lacidipine)

Study type: Observational

Funder types: Industry

Identifiers

NCT02235415

231.340

Details and patient eligibility

About

Study of the efficacy and tolerance of Motens® (lacidipine) in patients with essential hypertension. To obtain information on the dosage used in practice and the tolerance at the start of treatment (12 weeks)

Enrollment: 24,526 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Non-hospitalised patients of both sexes aged 18 years or more with essential hypertension requiring treatment according to the recommendations of the German League for Hypertension

Exclusion criteria

Patients who had the contraindications listed in the product information (the case report file contained a copy of the product information)

Trial design

24,526 participants in 1 patient group

Motens

Treatment:

Drug: Motens® (lacidipine)